Maravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance

Dow Jones

01-09

By Connor Hart

Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook.

The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million.

Shares fell 1.6%, to $6.03, in after-hours trading.

It plans to release its fourth-quarter and full-year operating results after the market closes on Feb. 25.

Maravai also on Wednesday said it would eliminate Andrew Burch's role as president of the company's nucleic acid production division, effective Jan. 16. Following Burch's departure, CEO Trey Martin will assume direct responsibility of the segment.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

January 08, 2025 16:43 ET (21:43 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2502085049"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502085049\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502085049?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 05:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502085049","market":"sg","top_or_hot":-1,"title":"Maravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. \n</p>\n<p>\n  The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million. \n</p>\n<p>\n  Shares fell 1.6%, to $6.03, in after-hours trading. \n</p>\n<p>\n  It plans to release its fourth-quarter and full-year operating results after the market closes on Feb. 25. \n</p>\n<p>\n  Maravai also on Wednesday said it would eliminate Andrew Burch's role as president of the company's nucleic acid production division, effective Jan. 16. Following Burch's departure, CEO Trey Martin will assume direct responsibility of the segment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 16:43 ET (21:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Maravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMaravai LifeSciences Holdings Projects 2024 Revenue Near Midpoint of Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 05:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. \n</p>\n<p>\n  The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million. \n</p>\n<p>\n  Shares fell 1.6%, to $6.03, in after-hours trading. \n</p>\n<p>\n  It plans to release its fourth-quarter and full-year operating results after the market closes on Feb. 25. \n</p>\n<p>\n  Maravai also on Wednesday said it would eliminate Andrew Burch's role as president of the company's nucleic acid production division, effective Jan. 16. Following Burch's departure, CEO Trey Martin will assume direct responsibility of the segment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2025 16:43 ET (21:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRVI","symbol_name":"Maravai LifeSciences Holdings, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502085049","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502085049","pubTimestamp":1736372580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook.The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million.Shares fell 1.6%, to $6.03, in after-hours trading.It plans to release its fourth-quarter and full-year operating results after the market closes on Feb. 25.Maravai also on Wednesday said it would eliminate Andrew Burch's role as president of the company's nucleic acid production division, effective Jan. 16. Following Burch's departure, CEO Trey Martin will assume direct responsibility of the segment.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MRVI":"Maravai LifeSciences Holdings, Inc."},"translate_title":"Maravai LifeSciences Holdings预计2024年收入接近指导中点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRVI":1},"content_text":"By Connor Hart \n\n\n \n\n\n  Maravai LifeSciences Holdings said Wednesday it expects to report full-year revenue for 2024 near the midpoint of its most recent outlook. \n\n\n  The San Diego company has guided for full-year revenue between $255 million and $265 million. Analysts polled by FactSet had forecast revenue of $259.8 million. \n\n\n  Shares fell 1.6%, to $6.03, in after-hours trading. \n\n\n  It plans to release its fourth-quarter and full-year operating results after the market closes on Feb. 25. \n\n\n  Maravai also on Wednesday said it would eliminate Andrew Burch's role as president of the company's nucleic acid production division, effective Jan. 16. Following Burch's departure, CEO Trey Martin will assume direct responsibility of the segment. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2025 16:43 ET (21:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}